Cantor upgrades Fulcrum to Overweight on sickle cell opportunity

Cantor Fitzgerald last night upgraded Fulcrum Therapeutics (FULC) to Overweight from Neutral with a $10 price target Today’s share valuation is reflecting very little credit for pociredir, which is likely to have a role in a “very large” sickle cell disease market, the analyst tells investors in a research note. The firm says that with 100,000 U.S. patients, pociredir could be a drug to consider for many. Cantor says its physician feedback has been mixed, but still supports a role for pociredir.